A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma

Cancer

Volumn 95, Issue 9, 2002, Pages 2000-2005

  Akerley, Wallace ^a,d   Rathore, Ritesh ^b   Ready, Neil ^c   Leone, Louis ^c   Sikov, William ^c   Safran, Howard ^c   Kennedy, Teresa ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c Brown University Oncology Group   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Carboplatin; Paclitaxel; Phase I; Weekly

Indexed keywords

BILIRUBIN; CARBOPLATIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 0036841024     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10902     Document Type: Article

References (18)

1. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860-1870.
2. Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer [review]. Semin Oncol. 2000;27(3 Suppl 7):3-7.
3. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88:124-131.
4. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol. 1998;16:255-260.
5. Aggarwal L, Akerley W, Wingate P, Leone L. Weekly paclitaxel - Effect on platelets in patients with NSCLC and in patients with prostate cancer and thrombocytopenia [abstract]. Proc Am Soc Clin Oncol. 1998;7:52a.
6. Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood. 2001;97:638-644.
7. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol. 1994;12:2682-2686.
8. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced cell lung cancer. J Clin Oncol. 1998;16:153-158.
9. Choy H, Safran H, Akerley W, et al. Phase II trial of paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 1998;4:1931-1936.
10. Akerley W, Choy H, Safran H, et al. Weekly paclitaxel in patients with advanced lung cancer: Preliminary data from a phase II trial. Semin Oncol. 1997;24 (suppl 12):S12-10-S122-13.
11. Schneiderman MA. The modified fibonacci (mouse to man: Statistical problem in bringing a drug to clinical trial) In: LeCain LM, Neyman J, editors. Proceedings of the 5th Berkeley Symposium on Mathematical Statistical Probability. Berkeley: University of California Press, 1967:855-856.
12. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
13. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
14. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996;14:1858-1867.
15. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KID, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654-2666.
16. Sarosy G, Kohn E, Stone DA, et al. Phase I study of Taxol and granulocte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992;10:1065-1070.
17. Belani CP, Barstis J, Perry M, et al. Phase II multicenter randomized trial of weekly paclitaxel (P) administered in combination with carboplatin (C) followed by maintenance P vs. observation for patients (pts.) with advanced and metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2001;20:323a.
18. Ready N, Chougule P, Wanebo H, et al. Induction chemotherapy with weekly paclitaxel and carboplatin, followed by concurrent paclitaxel, carboplatin and radiotherapy in advanced head and neck squamous cell cancers: A phase II study [abstract]. Proc Am Soc Clin Oncol. 2001;20:201b.